US FDA 2009 drug safety warnings analysed

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2012年 / 1388卷 / 1期

关键词：

Regulatory Action; Suicidal Behaviour; Bupropion; Varenicline; Efalizumab;

D O I：

10.2165/00128415-201213880-00011

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[1] The FDA and New Safety Warnings
Moore, Thomas J.
Singh, Sonal
Furberg, Curt D.
[J]. ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (01) : 78 - 80
[2] Update on the Office of Drug Safety at the US FDA
[J]. Reactions Weekly, 2004, 1015 (1) : 3 - 4
[3] US FDA reports new steps in drug safety
[J]. Reactions Weekly, 2007, 1138 (1) : 3 - 3
[4] US FDA enhancing postmarketing drug safety surveillance
[J]. Reactions Weekly, 2019, 1780 (1) : 3 - 3
[5] Report on Drug Safety and the US FDA by the Institute of Medicine
Anthony W. Fox
[J]. International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
[6] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
[J]. PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[7] The US FDA requires a “new vision of drug safety”
[J]. Reactions Weekly, 2006, 1126 (1) : 3 - 3
[8] US FDA to enhance warnings on antidepressant labelling
[J]. Reactions Weekly, 2004, 1020 (1) : 2 - 2
[9] Effects of FDA Safety Warnings May Vary
Kuehn, Bridget M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (09): : 894 - 895
[10] The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
Anand K.
Sketris I.
Zhang Y.
Levy A.
Gamble J.-M.
[J]. Drugs - Real World Outcomes, 2017, 4 (4) : 215 - 223

← 1 2 3 4 5 →